Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

30 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and immunogenicity of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120 vaccine boost adjuvanted with MF59 or alum in healthy adults without HIV (HVTN 107): A phase 1/2a randomized trial.
Moodie Z, Andersen-Nissen E, Grunenberg N, Dintwe OB, Omar FL, Kee JJ, Bekker LG, Laher F, Naicker N, Jani I, Mgodi NM, Hunidzarira P, Sebe M, Miner MD, Polakowski L, Ramirez S, Nebergall M, Takuva S, Sikhosana L, Heptinstall J, Seaton KE, De Rosa S, Diazgranados CA, Koutsoukos M, Van Der Meeren O, Barnett SW, Kanesa-Thasan N, Kublin JG, Tomaras GD, McElrath MJ, Corey L, Mngadi K, Goepfert P; HVTN 107 Protocol Team. Moodie Z, et al. Among authors: andersen nissen e. PLoS Med. 2024 Mar 19;21(3):e1004360. doi: 10.1371/journal.pmed.1004360. eCollection 2024 Mar. PLoS Med. 2024. PMID: 38502656 Free PMC article. Clinical Trial.
Protein dose-sparing effect of AS01B adjuvant in a randomized preventive HIV vaccine trial of ALVAC-HIV (vCP2438) and adjuvanted bivalent subtype C gp120.
Chirenje ZM, Laher F, Dintwe O, Muyoyeta M, deCamp AC, He Z, Grunenberg N, Laher Omar F, Seaton KE, Polakowski L, Woodward Davis AS, Maganga L, Baden LR, Mayer K, Kalams S, Keefer M, Edupuganti S, Rodriguez B, Frank I, Scott H, Stranix-Chibanda L, Gurunathan S, Koutsoukos M, Van Der Meeren O, DiazGranados CA, Paez C, Andersen-Nissen E, Kublin J, Corey L, Ferrari G, Tomaras G, McElrath MJ; HVTN120 study team. Chirenje ZM, et al. Among authors: andersen nissen e. J Infect Dis. 2023 Oct 5:jiad434. doi: 10.1093/infdis/jiad434. Online ahead of print. J Infect Dis. 2023. PMID: 37795976
Dysfunctional effector memory CD8 T cells in the bronchoalveolar compartment of people living with HIV.
Mthembu M, Claassen H, Khuzwayo S, Voillet V, Naidoo A, Nyamande K, Khan DF, Maharaj P, Mitha M, Mhlane Z, Karim F, Andersen-Nissen E, Ndung'u T, Pollara G, Wong EB. Mthembu M, et al. Among authors: andersen nissen e. bioRxiv [Preprint]. 2023 May 8:2023.05.05.539571. doi: 10.1101/2023.05.05.539571. bioRxiv. 2023. PMID: 37205594 Free PMC article. Preprint.
Developing tuberculosis vaccines for people with HIV: consensus statements from an international expert panel.
Miner MD, Hatherill M, Mave V, Gray GE, Nachman S, Read SW, White RG, Hesseling A, Cobelens F, Patel S, Frick M, Bailey T, Seder R, Flynn J, Rengarajan J, Kaushal D, Hanekom W, Schmidt AC, Scriba TJ, Nemes E, Andersen-Nissen E, Landay A, Dorman SE, Aldrovandi G, Cranmer LM, Day CL, Garcia-Basteiro AL, Fiore-Gartland A, Mogg R, Kublin JG, Gupta A, Churchyard G. Miner MD, et al. Among authors: andersen nissen e. Lancet HIV. 2022 Nov;9(11):e791-e800. doi: 10.1016/S2352-3018(22)00255-7. Epub 2022 Oct 11. Lancet HIV. 2022. PMID: 36240834 Free PMC article. Review.
Achieving intracellular cytokine staining assay concordance on two continents to assess HIV vaccine-induced T-cell responses.
Dintwe OB, De Rosa SC, Huang Y, Flach BS, Manso B, Carter D, Omar FL, Schwedhelm KV, Yu C, Lu H, Morris D, Kee JJ, Voillet V, Stirewalt M, Hural J, Moodie Z, Frahm N, Cohen KW, McElrath MJ, Andersen-Nissen E. Dintwe OB, et al. Among authors: andersen nissen e. J Leukoc Biol. 2022 Nov;112(5):1167-1181. doi: 10.1002/JLB.5MA0522-668R. Epub 2022 Jul 22. J Leukoc Biol. 2022. PMID: 35866359 Free PMC article.
Analysis of the HIV Vaccine Trials Network 702 Phase 2b-3 HIV-1 Vaccine Trial in South Africa Assessing RV144 Antibody and T-Cell Correlates of HIV-1 Acquisition Risk.
Moodie Z, Dintwe O, Sawant S, Grove D, Huang Y, Janes H, Heptinstall J, Omar FL, Cohen K, De Rosa SC, Zhang L, Yates NL, Sarzotti-Kelsoe M, Seaton KE, Laher F, Bekker LG, Malahleha M, Innes C, Kassim S, Naicker N, Govender V, Sebe M, Singh N, Kotze P, Lazarus E, Nchabeleng M, Ward AM, Brumskine W, Dubula T, Randhawa AK, Grunenberg N, Hural J, Kee JJ, Benkeser D, Jin Y, Carpp LN, Allen M, D'Souza P, Tartaglia J, DiazGranados CA, Koutsoukos M, Gilbert PB, Kublin JG, Corey L, Andersen-Nissen E, Gray GE, Tomaras GD, McElrath MJ. Moodie Z, et al. Among authors: andersen nissen e. J Infect Dis. 2022 Aug 24;226(2):246-257. doi: 10.1093/infdis/jiac260. J Infect Dis. 2022. PMID: 35758878 Free PMC article. Clinical Trial.
High Asymptomatic Carriage With the Omicron Variant in South Africa.
Garrett N, Tapley A, Andriesen J, Seocharan I, Fisher LH, Bunts L, Espy N, Wallis CL, Randhawa AK, Miner MD, Ketter N, Yacovone M, Goga A, Huang Y, Hural J, Kotze P, Bekker LG, Gray GE, Corey L; Ubuntu Study Team. Garrett N, et al. Clin Infect Dis. 2022 Aug 24;75(1):e289-e292. doi: 10.1093/cid/ciac237. Clin Infect Dis. 2022. PMID: 35353885 Free PMC article.
Integrated analysis of multimodal single-cell data.
Hao Y, Hao S, Andersen-Nissen E, Mauck WM 3rd, Zheng S, Butler A, Lee MJ, Wilk AJ, Darby C, Zager M, Hoffman P, Stoeckius M, Papalexi E, Mimitou EP, Jain J, Srivastava A, Stuart T, Fleming LM, Yeung B, Rogers AJ, McElrath JM, Blish CA, Gottardo R, Smibert P, Satija R. Hao Y, et al. Among authors: andersen nissen e. Cell. 2021 Jun 24;184(13):3573-3587.e29. doi: 10.1016/j.cell.2021.04.048. Epub 2021 May 31. Cell. 2021. PMID: 34062119 Free PMC article.
Innate immune signatures to a partially-efficacious HIV vaccine predict correlates of HIV-1 infection risk.
Andersen-Nissen E, Fiore-Gartland A, Ballweber Fleming L, Carpp LN, Naidoo AF, Harper MS, Voillet V, Grunenberg N, Laher F, Innes C, Bekker LG, Kublin JG, Huang Y, Ferrari G, Tomaras GD, Gray G, Gilbert PB, McElrath MJ. Andersen-Nissen E, et al. PLoS Pathog. 2021 Mar 15;17(3):e1009363. doi: 10.1371/journal.ppat.1009363. eCollection 2021 Mar. PLoS Pathog. 2021. PMID: 33720973 Free PMC article.
Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials.
Moodie Z, Walsh SR, Laher F, Maganga L, Herce ME, Naidoo S, Hosseinipour MC, Innes C, Bekker LG, Grunenberg N, Mann P, Yu C, deCamp AC, Miner MD, Yates NL, Heptinstall J, Mkhize NN, Dintwe O, Frahm N, Cohen KW, Allen M, Hutter J, Wagner R, Pantaleo G, McElrath MJ, Tomaras GD, Morris L, Montefiori DC, Andersen-Nissen E, Gray GE, Gilbert PB, Kublin JG; NIAID HVTN 100 and HVTN 111 trial teams. Moodie Z, et al. Among authors: andersen nissen e. PLoS Med. 2020 May 22;17(5):e1003117. doi: 10.1371/journal.pmed.1003117. eCollection 2020 May. PLoS Med. 2020. PMID: 32442195 Free PMC article. Clinical Trial.
30 results